99% Apixaban CAS 503612-47-3

ʻO ka wehewehe pōkole:

inoa kemika:ʻO Apixaban
inoa ʻē aʻe:1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine -3-carboxaMide;1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,
5-dihydropyrazolo[3,4-c]pyridine-3-carboxaMide
Helu CAS:503612-47-3
Maʻemaʻe:99% min
Kumu:C25H25N5O4
Kaumaha Molekala:459.50
Nā waiwai kemika:ʻO Apixaban kahi pauka crystalline keʻokeʻo.He ʻano hou ia o ka waha Xa factor inhibitor, a ʻo kāna inoa kālepa ʻo Eliquis.Hoʻohana ʻia ʻo Apixaban no ka mālama ʻana i nā poʻe maʻi makua e hoʻopaʻa ʻia ana i ka ʻūhā a i ʻole ke kuli pani e pale ai i ka thromboembolism venous (VTE).

E hoʻouna i ka leka uila iā mākou

Huahana Huahana

Hōʻike

MEA	KANAWAI
Ka nana aku	Paʻa keʻokeʻo a keʻokeʻo
Maemae	≥ 99%

Palapala noi

ʻO Apixaban kahi ʻano hou o ka anticoagulant waha, he ʻano hou o ka mea hoʻopuʻi waha Xa, i hoʻohana ʻia e pale a mālama i nā ʻōpū koko.
ʻO Apixaban kahi mea paʻa waha Xa hou i hoʻomohala ʻia e Bristol-Myers Squibb a me Pfizer.Ma ke kāohi ʻana i kahi kumu coagulation koʻikoʻi Xa, pale ʻo apixaban i ka hana thrombin a me ka thrombosis.

Ma ʻApelila 26, 2007, hoʻolaha ʻo Bristol-Myers Squibb lāua ʻo Pfizer i kahi hoʻomohala hui ʻana o ka anticoagulant oral apixaban hou nona ka Bristol-Myers Squibb ma ke ʻano he mea hou i ka warfarin.
I ka Mei 2011, ʻo apixaban ka mea mua i ʻae ʻia no ka pale ʻana i ka thrombosis venous i nā poʻe maʻi makua e hana ana i ke kīpē elective hip a i ʻole ke kuli ma nā ʻāina 27 EU, Iceland a me Norewai.
Ma ka lā 20 o Nowemapa, 2012, ua ʻae ke Komisina ʻEulopa i ka ELIQUIS (apixaban) no ka pale ʻana i ka hahau a me ka embolism systemic i nā pākeke me ka non-valvular atrial fibrillation (NVAF) me hoʻokahi a ʻoi aʻe paha nā mea pilikia.
Ua ʻae ka Canadian Food and Drug Administration, Iapana, a me ka US Food and Drug Administration i ka ELIQUIS (apixaban) no ka pale ʻana i ka hahau ʻana a me ka systemic embolism i nā pākeke me ka non-valvular atrial fibrillation (NVAF) me hoʻokahi a ʻoi aku paha nā mea pilikia.
Ma ʻApelila 12, 2013, ELIQUIS (Apixaban), i hoʻolaha ʻia ma ka mākeke ma Kina.ʻO Apixaban kahi mea hoʻopaneʻe oral factor Xa no ka pale ʻana i ka thromboembolism venous (VTE) i nā poʻe maʻi maʻi e hele ana i ka ʻoki ʻoki ʻoki a i ʻole ke kuli.Hāʻawi kona hoʻokuʻu ʻana i kahi koho hou palekana a maikaʻi no ka anticoagulation ma hope o ke kaʻina orthopedic i ka hoʻomaʻamaʻa lapaʻau, a lawe mai i ka nūhou maikaʻi i nā poʻe maʻi Kina e hoʻololi ana i ka hip/knee elective.
Ua hōʻoia nā noiʻi maʻi e hoʻohālikelike ʻia me 40 mg subcutaneous injection o enoxaparin hoʻokahi manawa i ka lā, 2.5 mg o ELIQUIS (Apixaban) waha ʻelua i ka lā ʻoi aku ka maikaʻi i ka pale ʻana i nā hanana thromboembolic venous ma hope o ka hoʻololi ʻana o ka ʻūhā a i ʻole ke kuli, ʻaʻole e hoʻonui i ka pilikia o ka maʻi. kahe koko.